Palo Alto, CA —By integrating microvolume liquid biopsy proteomics, single-cell transcriptomics and artificial intelligence, the Mahajan research team created a powerful tool to examine disease mechanisms at the cell level in living humans. They refer to this approach as TEMPO (Tracing Expression of Multiple Protein Origins). Their findings were published in Cell.The tool identified protein signatures associated with specific cells. These cells could then be monitored in various eye diseases including retinitis pigmentosa, diabetic retinopathy, uveitis, and even Parkinson's disease.
The team created a short video presentation on TEMPO.